Editas Medicine Garners $120,000,000 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=40dabca8-96b7-4f49-9b03-3d2fac69de55 - Date
8/10/2015 - Company Name
Editas Medicine - Mailing Address
300 Third Street 1st Floor Cambridge, MA 02142 USA - Company Description
The company’s mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. - Website
http://www.editasmedicine.com - Transaction Type
Venture Equity - Transaction Amount
$120,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
With this financing, we have a strong foundation from which we can broadly develop our genome editing platform and advance multiple new therapies toward clinical trials. - M&A Terms
- Venture Investor
Investor - Venture Investor
Deerfield Capital - Venture Investor
Viking Global Investors - Venture Investor
Fidelity Management & Research Company - Venture Investor
T. Rowe Price - Venture Investor
Google Ventures - Venture Investor
Jennison Associates - Venture Investor
Khosla Ventures - Venture Investor
EcoR1 Capital Management - Venture Investor
Casdin Capital - Venture Investor
Omega Funds - Venture Investor
Cowen Capital Partners - Venture Investor
Alexandria Venture Investments - Venture Investor
Bill & Melinda Gates Foundation
